Advanced Small Animal Ultrasound Imaging - Vevo F2

项目摘要/摘要 该提案要求提供资金，用于购买最先进的Vevo F2高分辨率超声成像设备 系统(富士-Visualsonics)。该系统将被集成到临床前 心血管(PCC)核心设施，位于华盛顿大学心脏病学系/医学系 科罗拉多州丹佛安舒茨医学院。由于Vevo F2的高度先进技术， 这一系统将大大扩展PCC核心的现有能力，并将加强正在进行的工作， 科罗拉多大学的全系统合作。这项提议的长期目标是提供 先进的超声能力，有助于更详细地了解病理生理机制 并强调可转化为人类创新疗法的潜在治疗策略 疾病。我们的目标是尽可能做到最好的科学，并以数据为指导。有一台Vevo F2乐器 在我们的PCC Core中，无疑将帮助我们实现这一目标。 PCC核心的一个主要关注点是促进使用小鼠和大鼠心血管模型的研究， 肺、肾、代谢和肿瘤疾病。我们的最终目标是将这些研究成果转化为 将临床前模型转化为治疗人类毁灭性疾病的新疗法。我们合作 与整个校园和整个丹佛大都市区的研究小组密切合作，以了解 心肾心肺相通在心肾肺疾病发病机制中的作用 血管/右室重构。此外，我们有专注于血管硬化的合作， 啮齿动物血流受损、代谢性疾病、肿瘤转移、生物标志物发现和对比成像 型号(见图)。所有这些努力都将受益于收购Vevo F2仪器，这将 实现最先进的、无创的心脏结构和功能、肾脏、心脏 以及小鼠和大鼠模型中胰腺血流和肿瘤的形成。此外，这款高清电视 超声系统将为监测细胞的局部输送和治疗提供宝贵的工具 通过心脏内或门静脉注射的药物。这个 Vevo F2，它有许多与 临床仪器，将产生巨大的影响 关于美国国立卫生研究院资助的科罗拉多大学的研究 Anschutz医学院，并有可能 促进将基础科学发现转化为 人类疾病的创新治疗方法。 除了上述合作之外， 通过按服务收费的安排，PCC核心 为不同的调查人员群体提供服务，不仅是 AMC有两个独立的动物设施，但 同样在科罗拉多州儿童医院，洛奇 山区退伍军人医学中心和大学 科罗拉多州博尔德。我们也深深地致力于 协助早期调查人员获得 支持他们的第一笔NIH拨款的初步数据 申请。对于所有这些研究，我们雇用了两个 Vevo 2100仪器，位于 研究中心2的无病原体动物设施 (RC2)。升级到Vevo F2至关重要 以满足日益增长的需求，以及 大量项目的技术需求，这些项目有 测试了Vevo 2100仪器的极限，我们 2014年购买的。不仅是这项技术 乐器不如Vevo F2，但Vevo 从2023年开始，2100将不再由富士视讯提供服务。此外，Vevo 2100使用了 Windows XP操作系统，与科罗拉多大学的IT要求不兼容。 我们必须获得Vevo F2，以保持和促进尖端生物医学研究 科罗拉多大学。

PROJECT SUMMARY/ABSTRACT This proposal requests funds for the acquisition of a state-of-the-art Vevo F2 high-resolution ultrasound imaging system (FujiFilm-VisualSonics). This system would be integrated into and managed by the Pre-Clinical Cardiovascular (PCC) Core facility within the Division of Cardiology/Department of Medicine at the University of Colorado Denver Anschutz Medical Campus (AMC). Due to the highly advanced technology of the Vevo F2, this system would significantly expand the current capabilities of the PCC Core and would enhance on-going, system-wide collaborations at the University of Colorado. The long-term objective of this proposal is to provide advanced ultrasound capabilities that lead to a more detailed understanding of pathophysiological mechanisms and highlight potential therapeutic strategies that could be translated into innovative treatments for human diseases. Our goal is to do the best science possible and be guided by the data. Having a Vevo F2 instrument in our PCC Core would undoubtedly help us achieve this goal. A major focus of the PCC Core to facilitate studies employing mouse and rat models of cardiovascular, pulmonary, renal, metabolic and onocologic diseases. Our ultimate goal is to translate findings made in these pre-clinical models into novel therapeutics for the treatment of devastating diseases in humans. We collaborate closely with research groups across the campus, and the entire Denver metropolitan area, to understand the roles of heart:kidney and heart:lung cross-talk in the pathogenesis of cardiorenal disease and pulmonary vascular/right ventricular remodeling. Additionally, we have collaborations focused on vascular stiffening, impaired blood flow, metabolic disease, tumor metastasis, biomarker discovery and contrast imaging in rodent models (see Figure). All of these efforts would benefit from the acquisition of a Vevo F2 instrument, which would enable state-of-the-art, non-invasive, longitudinal measurements of cardiac structure and function, renal, cardiac and pancreatic blood flow, and tumor formation in mouse and rat models. In addition, this high-definition ultrasound system would provide an invaluable tool for monitoring localized delivery of cells and therapeutic agents via intra-cardiac or portal vein injection. The Vevo F2, which has many features in common with clinical instruments, would have a tremendous impact on NIH-funded research at the University of Colorado Anschutz Medical Campus, and has the potential to facilitate translation of basic science discoveries into innovative treatments for human disease. In addition to the aforementioned collaborations, through fee-for-service arrangements, the PCC Core serves a diverse group of investigators, not only on the AMC, which has two separate animal facilities, but also in the Colorado Children's Hospital, the Rocky Mountain Regional VA Medical Center, and University of Colorado Boulder. We are also deeply committed to assisting early stage investigators obtain preliminary data to support their first NIH grant applications. For all of these studies we employ two Vevo 2100 instruments, which are located in a pathogen-free animal facility in Research Center 2 (RC2). The upgrade to the Vevo F2 is crucially needed to meet the increasing demands, and technical needs, of a multitude of projects, which have tested the limits of the Vevo 2100 instruments that we purchased in 2014. Not only is the technology of this instrument inferior to that of the Vevo F2, but the Vevo 2100 will no longer be serviced by FujiFilm-VisualSonics starting in 2023. Furthermore, the Vevo 2100 uses a Windows XP operating system, which is not compatible with the IT requirements of the University of Colorado. It is essential that we obtain a Vevo F2 to maintain and promote cutting edge biomedical research at the University of Colorado.